Anaconda Biomed Secures $56 Million in Financing

Anaconda Biomed has closed a $56 million financing round led by Omega Funds and new investor Spain’s co-investment fund (FOCO, managed by COFIDES), as well as existing financiers Asabys (Sabadell Asabys II), Ysios Capital, and CDTI (through its SICC Innvierte).

The capital will support product development and clinical work, including completion of the ongoing ATHENA pivotal IDE study—a prospective, randomized, 327-subject trial intended to evaluate the safety and performance of the ANA Funnel Catheter.

“This latest funding round allows us to further advance our work in the acute treatment of those suffering a stroke, with the goal of reducing disability and death caused by large vessel occlusive disease,” Anaconda Biomed CEO Trent Reutiman said. “The support of this leading group of investors reflects the growing confidence in our technology platform, and the funds raised will ensure that the company has the required resources to complete the clinical and regulatory requirements. We sincerely appreciate the commitment of this prestigious group of investors.”

Anaconda’s proprietary Funnel Catheter platform is an endovascular technology designed to improve clot capture, reduce embolic complications, and maximize brain reperfusion. In combining aspiration power with flow-arrest and flow-reversal, the platform may address clot retrieval, fragmentation, and downstream embolization, taking on thrombectomy’s most persistent challenges. Anaconda’s product portfolio will include supplementary tools such as stent retrievers, sheaths, and guidewires that complement funnel catheter technology and pave the way for additional clinical applications.

Anaconda targets a large, underpenetrated, and expanding stroke intervention market. Strokes cause 7 million deaths annually; most of these episodes (65%) are ischemic strokes, and 30% of these patients are treated using mechanical thrombectomy. These numbers translate to nearly 270,000 mechanical thrombectomy procedures performed globally in 2026, but it represents only a fraction of the total addressable market, according to the company.

“Anaconda is bringing a next-generation solution to the large and growing ischemic stroke market,” Omega Funds Managing Director Claudio Nessi stated. “For millions of patients around the world, its portfolio of products offers hope for better treatment outcomes. With a very strong team, led by Trent Reutiman, we believe that Anaconda has the resources and unique technology to establish itself in the very active interventional neurovascular device market.”

Anaconda has established a state-of-the-art production facility on the edge of Barcelona. Direct control of the key development and manufacturing processes provides nimble, efficient and iterative product expansion capabilities. The company is establishing meaningful manufacturing trade secrets associated with its core technology.

Anaconda Biomed is a medical technology company striving to reduce disability and death caused by stroke and other neurovascular diseases. Anaconda’s proprietary Funnel Catheter platform is an endovascular technology designed to improve clot capture, reduce embolic complications, and maximize brain reperfusion. By combining aspiration power similar to large-bore catheters with the flow-arrest and flow-reversal benefits typically associated with balloon guide catheters, Anaconda seeks to capture microemboli before they cause new vessel occlusions, supporting more complete reperfusion, easier clot retrieval, and fewer device passes. Anaconda is developing a portfolio of products built on this technology, spanning mechanical thrombectomy, aspiration-first stroke treatment, and carotid interventions, including the ANA5, ANA6, ANA8, and the Conda stent retriever.

The ANA Funnel Catheter is an investigational device in the United States, limited by U.S. law to investigational use. The ANA5 Funnel Catheter is CE mark approved.